Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Evolent Health (NYSE:EVH) Stock Price

Headlines about Evolent Health (NYSE:EVH) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Evolent Health earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media stories about the technology company an impact score of 46.5786325466442 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s scoring:

Shares of Evolent Health (EVH) traded down $0.35 during trading on Monday, reaching $13.70. The company’s stock had a trading volume of 577,107 shares, compared to its average volume of 950,359. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34. The firm has a market cap of $1,070.00 and a P/E ratio of -12.02. Evolent Health has a 52-week low of $10.30 and a 52-week high of $27.50.

Several equities analysts have recently commented on EVH shares. Citigroup started coverage on Evolent Health in a research report on Thursday, January 4th. They issued a “buy” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Sunday, December 3rd. Leerink Swann set a $25.00 price target on Evolent Health and gave the stock a “buy” rating in a research report on Saturday, November 18th. Goldman Sachs Group downgraded Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. Finally, SunTrust Banks restated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $28.00.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Evolent Health (NYSE:EVH) Stock Price” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with's FREE daily email newsletter.

Leave a Reply